Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tempest Therapeutics ( (TPST) ) is now available.
On January 20, 2026, Tempest Therapeutics announced that its board set January 30, 2026 as the record date for a warrant dividend, under which shareholders and certain existing warrant holders received in total 6,784,989 warrants, each allowing the purchase of one share of common stock at a cash exercise price of $18.48 per share until their expiration on February 3, 2031, with exercisability contingent on effectiveness of a registration statement. On February 3, 2026, the company completed an asset acquisition from Erigen, issuing 8,268,495 shares of common stock in a private placement, and simultaneously implemented significant governance changes: director Geoff Nichol resigned, long-time chair Michael Raab transitioned the chair role to Stephen Brady, Brady then resigned as president and CEO, and biotech veteran Matt Angel was appointed president, CEO and director under a remuneration and severance package designed to align long-term incentives, while the company also formalized an employment agreement with executive Nicholas Maestas, collectively signaling a strategic repositioning of Tempest’s leadership, capital structure and asset base.
The most recent analyst rating on (TPST) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and significant cash burn with a shrinking equity cushion). Technicals remain soft with price below key longer-term averages and negative MACD. Corporate events are mixed (Nasdaq compliance risk vs. governance approvals), and valuation metrics offer limited support due to negative earnings and no dividend.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics is a biotechnology company focused on developing novel therapeutics, with operations centered on advancing its pipeline through strategic asset acquisitions, equity incentives and capital structure tools such as common stock, warrants and private placements.
Average Trading Volume: 152,737
Technical Sentiment Signal: Sell
Current Market Cap: $11.73M
Find detailed analytics on TPST stock on TipRanks’ Stock Analysis page.